1. Pharmacological inhibitors of cyclin-dependent kinases;Knockaerta;Trends Pharmacol. Sci.,2002
2. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures;Mason;J. Med. Chem.,1999
3. Müller, G. (2001) Structural bioinformatics meets rational drug design. (http://www2.chemie.uni-erlangen.de/external/cic/tagungen/gdch2001/mueller/abstract.html)
4. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C;Jirousek;J. Med. Chem.,1996
5. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases;Sun;J. Med. Chem.,1998